How Moderna became a pioneer of mRNA technology

• Moderna experiences a rapid rise within 13 years
• History started in 2005 at Stanford University
• Moderna occurs due to COVID-19 first quarterly profit in the company history

Stanford University’s postdoctoral level the way for Moderna

Moderna’s history began in 2005 at Stanford University. There, the 39-year-old stem cell biologist and postdoctor Derrick Rossi came across a scientific treatise by the Hungarian biochemist Catalin Karikó about RNA-mediated immune activation, written together with the US immunologist Drew Weissman. Rossi immediately recognized the groundbreaking potential of this new technology. Years later, according to the science magazine, he said that Karikó and Weissman deserved the Nobel Prize for Chemistry. (In fact, Karikó and Weissman were awarded the Nobel Prize for Medicine in 2023.) When Rossi received an assistant professorship at the Harvard Medical School in 2007, he initially did not research on vaccines, but whether Boten-RNA could be the key to creating embryonic stem cells. His goal was to cure diseases such as Parkinson’s or spinal cord injuries through such cells. He also hoped to solve an ethical dilemma, because embryonic stem cells mostly come from aborted embryos.

Rossi therefore reproduced adult cells so that they behaved like embryonic stem cells. In 2009 he made the breakthrough: under his microscope he discovered a plate of cells exactly the way he wanted to create. This success paved the way to start the company.

2010: Moderna is founded

After Rossi’s breakthrough, he turned to his colleague Timothy Springer, professor at the Harvard Medical School and Biotech entrepreneur. Springer recognized the commercial potential and added the mit biomedic medicine professor Robert Langer. According to the business magazine Forbes, Springer invested $ 5 million in the new company “Moderna Therapeutics”. In addition to Rossi, Springer and Langer, the risk capitalist Noubar Afeyan and the cardiologist Kenneth Chien were also among the co -founders. In 2011 the young company began developing MRNA drugs, and Stéphane Bancel took the lead as a founding CEO. There were no profits at first. Nevertheless, Moderna expanded in 2014 and opened new headquarters and laboratories in Cambridge, Massachusetts.

However, internal disputes led to setbacks: Founders Derrick Rossi left the company after inconsistencies with Langer and Afeyan. Rossi accused them of spreading the “myth” that he had not recognized the full potential of his discovery, while Langer replied that Rossi had discovered important things but focused too much on stem cells. In November 2017, Moderna achieved another scientific milestone. Employees found that mRNA is a very unstable molecule and therefore needed protective transport systems to work in the body. Research paid off: In 2017, Moderna tested its own active ingredient to humans – the combination vaccine MRNA -1653 against two respiratory viruses (HMPV and Parainfluenza). In 2018 the largest IPO in Biotech history followed. Moderna also opened a clinical development center in Norwood and turned itself into today’s “Moderna” from “Moderna Therapeutics”. The name is made up of “Modified RNA”, as the company website explains.

Moderna creates the first quarter of the company history

By 2020, Moderna had numerous promising projects, but no product on the market yet. Accordingly, the company previously increased losses of around $ 1.7 billion, as the Neue Zürcher Zeitung (NZZ) reported. But with the outbreak of Covid-19, Moderna became a pioneer of vaccine research. Through early partnerships with pharmaceuticals such as Merck, Astra Zeneca and Vertex, as well as by advance booking with various states, Moderna finally has – as of the mid -2020 – a liquid funds of $ 4 billion. In the first nine months of 2020, Moderna only achieved $ 46 million sales – not even enough to cover the administrative costs. For research and development alone, Moderna spent $ 378 million during this period. But thanks to sufficient financial reserves and the prospect of an effective vaccine, the company survived this phase. At the end of 2020, the US health authority CDC recommended the use of the moderna vaccine from the age of 18. Moderna then wrote blacks for the first time in the first quarter of 2021. With the global vaccination program, Moderna rose to new dimensions. By May 2022, more than 30.5 million people were vaccinated in Germany at least once with modern vaccin. By the end of 2021, the company delivered a total of 807 million doses of its COVID 19 vaccine. Around 25 percent of them went to countries with low or medium -sized incomes – partly directly, partly through international donation programs. In 2021, Moderna achieved annual sales of $ 17.7 billion and a net profit of $ 12.2 billion. In the following year 2022, the proceeds even increased to $ 19.3 billion before the 2023 vaccine demand decreased significantly.

Moderna’s new production facility in Laval near Montreal, which is part of a ten -year partnership with the Canadian federal government and the Province of Québec, should originally produce up to 100 million vaccine doses per year from 2024. In fact, the state -of -the -art work was completed in early 2024. In September 2024 it received the manufacturing license of the Canadian authorities, so that from 2025 mRNA vaccines against Covid-19, RSV and flu can be produced. In Canada, too, Moderna underlines its long -term commitment to the supply of vaccine in their own country. At the same time, Moderna 2022 received a cooperation with the University of Toronto in order to jointly develop new funds for the prevention and treatment of infectious diseases – for example in molecular genetics, biomedicine technology and biochemistry.

Diversification: MRNA beyond Covid-19

After the end of the acute pandemic, Moderna has significantly expanded its focus: In addition to Covid-19, the company is now focusing on new MRNA-based vaccines-such as against cancer, RSV, flu and cytomegalovirus (CMV).

These progress in product development marks a significant step in the diversification of the MRNA portfolio and underpin Moderna’s claim to also play a leading role in the field of innovative vaccines in the long term.

Editor finance.net

Selected leverage products on AstraZeneca

With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired lever and we will show you suitable open-end products on AstraZeneca

The lever must be between 2 and 20

Advertising